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Abstract 
  Arsenic, the environmental metalloid toxicant, is known to induce oxidative damage to 
liver and produces hepatic fibrosis. The theme of our study was to optimise and evaluate 
the therapeutic efficacy of galactosylated liposomal flavonoidal antioxidant [Quercetin 
(QC)] in combating arsenic induced hepatic fibrogenesis. The rats of the hepatic damage 
group were injected (s c) a single dose of sodium arsenite (NaAsO2) (100.06 µM / kg b 
wt in 0.5 ml of physiological saline). Hepatocytes and stellate cells were separated. 
Mitochondrial membranes were isolated from all those separated cells. Oxidative damage 
was monitored at different isolated sub-cellular parts of different hepatic cells. Liver 
fibrosis was also induced by the injection of NaAsO2. Galactosylated liposomal QC 
injection prior to NaAsO2 treatment checked fibrogenesis completely by protecting the 
liver from oxidative attack in cellular and subcellular levels. The maximum protection 
from hepatocellular and fatty metamorphosis, necrosis, Kupffer cell hyperplasia, fibrosis 
and in the deposition of collagen contents were observed and reconfirmed by our 
histopathological and histochemical analysis when rats were treated with galactosylated 
liposomal QC prior to NaAsO2 injection. Application of galactosylated liposomal QC 
may be a potent therapeutic approach for NaAsO2 induced fibrogenesis through a 
complete protection against oxidative attack in cellular and subcellular parts of rat liver. 
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 Introduction 
  Arsenic the naturally occurring metalloid has been recognized as environmental toxicant 
and its contamination of drinking water is a serious environmental calamity worldwide 
because of the million of people at risk, particularly in developing countries such as West 
Bengal in India and Bangladesh (Chatterjee et al., 1995). An important feature in arsenic 
toxicity is in a form of hepatic fibrosis that causes portal hypertension (Guha Mazumder 
et al., 1998). Although mechanism(s) by which arsenic induces hepatic fibrosis remains 
poorly understood, however, the common theme that was emerged is the role of reactive 
oxygen species (ROS) in the pathogenesis of arsenic-induced hepatic fibrosis. Hepatocyte  
necrosis itself may activate lipocytes. Such activation could be mediated by the lipid 
peroxides formed after the membrane of the hepatocyte is injured (Greenwel et al., 2000). 
The critical event in hepatic fibrosis is the activation of lipocytes (Stellate, fat storing or 
Ito cell), the main source of extracellular matrix in fibrosis formation (Du et al., 1999). 
    Complementary approach that delineates the NaAsO2 induced contribution of ROS 
includes the use of antioxidants, superoxide dismutase (SOD) and catalase. But 
introduction of either SOD or catalase can only suppress a little part of toxic oxygen 
species that is generated by the induction of NaAsO2 (Kessel et al., 2002). 
    Non-enzymatic supplementation as a protective strategy has also resulted in conflicting 
outcomes in in vivo experiments. Administration of D-α-tocopherol to rats provided no 
protection against ROS in liver diseases. So the present challenge is to counter NaAsO2 
induced oxidative attack and to isolate a non-toxic antioxidant that can be selectively 
targeted to liver, which provide an even distribution in intra hepatic membrane.  
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    Liposomes are accepted as potent drug carriers not only for its biocompatible nature 
but also those phospholipid vesicles do not elicit negative biological responses that 
generally occur when a foreign material is introduced in the system. Furthermore, owing 
to the presence of galactosyl receptor on the surface of hepatocytes, galactosylated 
liposomes are effective in the site-specific drug delivery to hepatic tissue with a 
homogenous intrahepatic membrane distribution of its intercalated components (Sinha et 
al., 2000). The mammalian liver consists primarily of hepatocytes and stellate cells . The 
membrane composition of liposome is crucial for its targeting and function. It was 
observed that galactosylated liposomes entrapped material was largely taken up by 
hepatocytes. The high endocytic activity of sinusoids lining cells makes them most  
competent to internalise colloidal particles like liposomes. So, natural targeting of 
liposomes takes place by those cells and it is reasonable to assume that galactosylated 
liposome administration increases intracellular accumulation of vesicular content in 
hepatocytes (Manajit et al., 2005). 
    Quercetin, the most abundant flavonoid in nature, presents in large amounts in 
vegetable, fruits, tea and olive oil and as it contains a numbers of phenolic hydroxyl 
groups, it exhibits its therapeutic potential against many diseases, including ischemic 
heart diseases, atherosclerosis, liver fibrosis, renal injury and in chronically biliary 
obstruction (Peres et al., 2000; Sing et al., 2004; Tokyol et al., 2006; Lee et al., 2003).  In 
the light of the above observations it seems reasonable to expect that administration of 
QC in galactosylated liposomes might contribute to reduce NaAsO2 induced oxidative 
damage in cellular or sub-cellular parts of hepatic tissue and provide a protective 
mechanism against liver fibrosis. 
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  Despite the fact that rats unlike other mammals retain the dimethyl arsinic acid, one of 
the intermediate metabolites of NaAsO2 in the blood, studies were performed in this 
report on rats because this species is known superior to others in forming monomethyl 
arsonous acid (Csanaky and Gregus, 2002). Monomethyl arsonous acid is most toxic 
among other NaAsO2 metabolic intermediates to rat as well as human hepatocytes 
(Styblo  et al., 2000).  
The purpose of our in vivo studies is to ascertain whether treatment with QC intercalated 
in galactosylated liposomes exerts any hepatoprotective effect against NaAsO2 induced 
fibrosis in liver. 
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Materials and methods 
 Materials 
  Phosphatidyl ethanolamine (PE), cholesterol, dicetyl phosphate (DCP), p-amino phenyl 
α-D-galactoside, glutaraldehyde, collagenase, diphenyl hexatriene (DPH), triton x-100, 
glutathione reductase, were purchased from Sigma Chemicals (St. Louis, MO, USA). 
Sodium arsenite from E.Merck, Germany was used for experimental purpose. 
Chloramine-T, Fast Green FCF and Sirius Rose BB were acquired from Loba-Chemie 
and Fluka respectively whereas chloroform and methanol were from E.Merck (India) Ltd. 
Quercetin was isolated and purified from Fagopyrum esculentum (buck wheat).  All other 
reagents were of analytical grade. 
 
 Preparation of liposomal QC and Coupling of p-aminophenyl α-D galacto-pyranoside 
with liposomes  intercalated with QC 
  Multilamellar liposomes were prepared with Phosphatidyl Ethanolamine (PE), 
Cholesterol, Dicetyl Phosphate (DCP) and Quercetin (QC) in molar ratio 7:1:1:1 (Budai 
and Szoqvi, 2001).  In short PE, Cholesterol, DCP and QC are dissolved in chloroform 
and methanol mixture (2:1, v/v) in a round bottom flask.  The lipid film was made by 
drying the organic solvents and was desiccated over night.  The thin film was swollen in 
PBS (pH 7.2) for 1 h and sonicated in a probe type sonicator for 30 s. 
  Liposomal QC was coupled with p-aminophenyl α-D galacto-pyranoside by using 
glutaraldehyde as the coupling agent (Mitra et al., 2005). 
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 Animal and Experimental design 
  Adult male Swiss Albino rats, each weighing 120-150g were acclimatized to conditions 
in the laboratory (26-28OC, 60-80% relative humidity, 12 h light/dark cycle) for 10 days 
prior to the commencement of the treatment during which they received food (purchased 
from Hindustan Lever) and drinking water. Rats were divided into six groups with 5 
animals in each group. Rats in the normal group were injected subcutaneously (s c) with a 
single dose of physiological saline (0.5ml) at multiple sites.  Rats in the NaAsO2 treated 
group were injected (s c) with NaAsO2 (100.06 µM/kg body weight in 0.5 ml 
physiological saline) at five different sites of its abdominal skin by making a 10 s time 
gap between one injection to its next. Free drug (0.5 ml suspension of 0.2% tween 80 
aqueous solution containing 0.898 µM QC) was injected into tail vein of third group of 
rats 2 h before NaAsO2 treatment. Liposome with QC (0.5 ml suspension containing 
0.898 µM QC), empty galactosylated liposome or galactosylated liposome intercalated 
with QC (0.5 ml suspension contain 0.222, 0.445, 0.898 or 1.335 µM QC) was injected 
into tail vein of rats in those different experimental groups 2 h before NaAsO2 treatment. 
QC uptake by liver was estimated in the other groups of rats after 2 h of injection of free 
QC,  liposomal QC or galactosylated liposomal QC. 
   For LD50 determination, a single dose of NaAsO2 (84.67-130.8 µM/kg body weight) 
was injected to each group of rats subcutaneously.  
    Twenty-four hours after NaAsO2 administration the rats of all groups were 
anaesthetized with ether and blood was collected from heart. Serum aspartate 
transaminase (AST), alkaline phosphatase (AP) (Karim et al., 2001; Tyagi et al., 2005) 
and serum urea and creatinine were determined using a standard kit.  Animals were 
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sacrificed immediate after collecting blood.  The liver was promptly removed and a part 
of the organ was immediately fixed in Bouin’s fixative and processed for histological 
examination.  All the rats used in this study received proper care in compliance with 
animal Ethics Committee, India. Liver histochemistry for collagen and liver tissue 
histology were studied by microscopic examination (Lin et al., 2005).   
    Perfusion of liver and separation of sub-cellular fractionations were done (Sinha et al., 
2000). Mitochondria were separated and purified with Percoll gradient. The purity and 
yield of the mitochondrial membrane fractions were assayed using standard subcellular 
markers (Tirmenstein and Nelson, 1989).  
 
 Biochemical analysis and enzyme assays 
 Lipid peroxidation Assay  
   Lipid peroxidation in the mitochondrial membrane was determined by measuring the 
amount of conjugated diene. The mitochondrial membrane was extracted twice in 
chloroform-methanol mixture (2:1 v/v). The pooled extract was evaporated to dryness 
under nitrogen atmosphere at 25oC and redissolved in cyclohexane.  Lipids in 
cyclohexane solvent was assayed at 234 nm and the results were expressed as µmol of 
lipohydroperoxide / mg protein by using an ∈m of 2.52 x 104 L mol-1 cm-1 (Mandal et al., 
2002).  
 
 Quantitation of Quercetin level in liver 
   Liver homogenates of normal and experimental rats were diluted with an equal volume 
of absolute ethanol containing 1 µg/ml butylated hydroxyanisole. One ml of n-heptane 
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was added and the whole suspension was vortexed. This sample was centrifuged at 
1000 rpm for 5 min at 4oC. The heptane layer was removed and another 1 ml of fresh n-
heptane added. The sample was centrifused as earlier until three volumes of heptane had 
been added. These volumes were combined and dried under nitrogen atmosphere. The 
residue was dissolved in 0.2 ml of methanol and 20 µl was injected onto a high-
performance liquid chromatography (HPLC) column and quantitation of Quercetin in 
liver homogenate was performed spectrophotometrically (Mandal and Das, 2005). 
  
 Different enzyme  activities     
Rat liver was perfused with the perfusion buffer (125 mM NaCl, 2.47 mM KH2 PO4, 15 
mM Na2HPO4, 5 mM NH4Cl, 34.01mM CaCl2.2H2O, 5mM glucose, 0.2% BSA having a 
pH 7.2) containing collagenase and CaCl2 at 37°C through the portal vein of the animal 
for 10 min at a rate of 10 to 15 ml/min. The tissue was chopped, homogenized in ice-cold 
perfusion buffer containing BSA (2g/L) and filtered through a nylon gauge (110 mesh). 
The cell suspension was centrifuged at 50xg for 4 min. The pellet was resuspended, 
washed and collected as hepatocytes. The supernatant was then centrifuged at 500xg for 9 
min to precipitate stellate cells. The isolated stellate cells were further purified with 
Percoll gradient. The cells were resuspended in 9.3 ml of perfusion buffer and mixed with 
12.7 ml of Percoll containing 1/10 volume of 10-fold concentrated perfusion buffer. After 
centrifugation at 20,000xg for 10 min at 4°C, the cell layer above the 1.07 gradient was 
carefully recovered. Thus, stellate cells were collected and resuspended in buffer. The 
hepatocytes and stellate cell suspensions were homogenized at 4°C with 10 up and down 
JPET #114215                                                                                                                                                11
strokes in a glass homogenizer fitted with a Teflon pestle. The homogenates were 
centrifuged at 105,000 g for 60 min to get cytosolic fractions. 
 Catalase activity 
  The cytosolic fractions, thus obtained, were used for enzyme activities. Catalase activity  
was assayed (Moragon et al., 2005). The reaction mixture contained sodium phosphate 
buffer (0.05 M, pH 7.0), 50 mmol/L-1 H2O2 and 50 µl of enzyme extract in a 3 ml 
volume. The activity was assayed by monitoring the decrease in absorbance at 240 nm as 
a consequence of H2O2 consumption and enzyme activity expressed as amount of H2O2 
decomposed per min per mg of protein. 
 
 Glutathiane peroxidase (GPx) activity 
  The GPx activity was determined (Sarkar and Das, 2006). The cytosol, containing the 
enzyme source was mixed with 0.25 M potassium phosphate buffer, 25 mM EDTA, 
glutathione reductase, 40 mM glutathione (GSH), 20mM NADPH. The mixture was 
mixed and then incubated for 2 min at 37°C. The reaction was initiated by adding t-butyl 
hydroperoxide at the final concentration of 0.3mM. The mixture was stirred and the 
absorbance was read immediately at 340 nm at 1-min intervals for 4 min. The absorbance 
change during the 2 to 4 min interval was used to calculate enzyme activity. The activity 
was determined and expressed as µmol NADPH oxidized/min/mg protein. 
 
 Glutathione reductase (GR) activity 
 GR was assayed (Castro et al., 1990). A 3 ml reaction mixture contained 100 mM 
phosphate buffer (pH 7), 1 mM GSSG, 1mM EDTA, 0.1 mM NADPH, and 25 to 50 µl 
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enzyme extract. The reaction was started by adding the enzyme extract. The rate of 
NADPH oxidation was followed by monitoring the decrease in absorbance at 340 nm 
with a recording spectrophotometer.  The activity was expressed as µmol of NADPH 
oxidation/min/mg protein.  
 
Glutathione – S – transferase (GST) activity 
 GST activity was determined in a total volume of 1.0 ml, containing 100mM potassium 
phosphate buffer (pH 6.5) and 2 mM each of GSH and 1-chloro-2-4-dinitrobenzene (final 
concentration). The rate of formation of S-2,4-dinitrophenylglutathione (a GSH-1-chloro-
2,4-dinitrobenzene conjugate) by enzyme extract was quantified at 340nm using the 
extinction coefficient of 9.6 L mmol-1 cm-1 (Maiti and Chatterjee, 2000) and the activity 
was expressed as n mol/min/mg protein.  
 
 Glucose – 6-phosphate dehydrogenase (G6PDH) activity 
  The G6PDH activity was determined using a Sigma Diagnostics Kit which is based on a 
modification of Spectrophotometric method (Maiti and Chatterjee, 2000). G6PDH 
catalyses the first step in the pentose phosphate pathway, oxidising glucose-6-phosphate 
to 6-phosphogluconate and reducing nicotinamide adenine dinucleotide phosphate 
(NADP) to NADPH. The rate of formation of NADPH is proportional to G6PDH activity 
and was measured spectrophotometrically as an increase in absorbance at 340 nm. One 
unit of G6PDH activity was defined as 1µM NADPH produced per min. 
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  Fluorescence Depolarisation Measurements of the fluidity of mitochondrial 
membrane 
  The fluorescence depolarisation, associated with the hydrophobic fluorescence probe 
DPH, was used to monitor the changes in the fluidity of the lipid matrix accompanying 
the gel to liquid crystalline phase transition.  Mitochondrial membrane fractions of 
hepatic cells were incubated at 37oC by the addition of DPH dissolved in tetrahydrofuran 
(DPH/lipid molar ratio 1:500).  The excitation and the emission maxima were kept at 365 
and 430 nm respectively.  The fluorescence anisotropy was calculated by using the 
equation 
r = (III – I⊥) / (III + 2I⊥)  ………………(1) 
where III and I⊥ are the fluorescence intensities in parallel and perpendicular to the 
direction of polarization of the excited light. The micro viscosity parameters [(ro/r)-1]-1 
were calculated in each case, knowing the maximal limiting fluorescence anisotropy ro 
which for DPH is 0.362 (Sarkar et al., 2002). 
  
 Estimation of hepatic 4-hydroxyproline (4-HP) 
   The liver was cut into small pieces and homogenised in sufficient deionized water to 
yield 10% homogenate (W/V). Aliquots (2 ml) of the homogenate were added to an equal 
volume of 12 N HCl and hydrolysed in Teflon capped vials at 105˚C for 18 h. 4-HP 
levels from those hydrolysates were measured (Sarin et al., 1999). The absorbance at 558 
nm was read and values were plotted against a standard graph using known amounts of 4-
HP.  
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 Estimation of total hepatic collagen 
   The technique (Sarin et al., 1999) was used which is based on selective binding of 
Sirius Rose BB and Fast Green FCF to collagen and non-collagen components, 
respectively. When the sections are stained with both dyes dissolved in aqueous saturated 
picric acid, they are eluted readily with NaOH and simultaneously the absorbance 
obtained at 550 and 625 nm can be used to determine the amount of collagen and total 
protein respectively. 
 
 Arsenic analysis 
  Sub-cellular fractions were digested with acid mixture containing nitric acid, sulfuric 
acid and perchloric acid in the ratio of 6:1:1, over a regulated heater. After the digestion, 
the acid mixture was evaporated with occasional addition of triple distilled water and the 
solution thus obtained was employed for estimation of arsenic content. Estimation was 
carried out using the atomic absorption spectrophotometer (Spectra AA 30/40; Varian, 
Australia) fitted with a graphite furnace (Flora et al., 1995). 
  
Statistical analysis 
  Statistical analysis was performed with student’s t-test.  Linear correlation between two 
data was calculated by means of Pearson’s correlation coefficient r. In all instances, 
P<0.05 was considered as the minimum level of significance. 
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Results 
 Acute NaAsO2 induced mortality in rats 
  A single injection of NaAsO2 produced a dose dependent mortality in rats (Fig.1). 
Arsenite induced mortality at a dose of arsenic higher than 84.67µM/kg b wt and no rats 
survived the dose of 130.8 µM/kg. The LD50 value for arsenic-induced lethality in the 
rats was 107.75µM/kg.  
 
Effect of QC in galactosylated liposome on arsenic deposition in mitochondria of 
different hepatic cells 
  A single dose of NaAsO2 injection (s.c.) (100.06µM/kg b wt) resulted a deposition of 
arsenic in mitochondria of hepatocytes and stellate cells in the level of 264±24 and 
252±18 µg/g mitochondrial protein. The elevated arsenic level in experimental animals 
was found reduced maximally by the treatment with QC in galactosylated liposomes 
(Fig.2a&2b) where arsenic content was not detected by atomic absorption 
spectrophotometer in normal rats. 
 
Correlation of mitochondrial arsenic content of hepatocytes and stellate cells with lipid 
peroxidation 
  Figure 3a shows positive correlation (r =0.97, P<0.001) between hepatocytic 
mitochondrial arsenic level and its conjugated diene level. The increased stellate 
mitochondrial arsenic level was also found to be associated with its increased lipid 
JPET #114215                                                                                                                                                16
peroxidation as was evident from a significant positive correlation (r = 0.93, P<0.001) 
(Fig.3b) between its arsenic and conjugated diene content.  
 
Effect of QC in galactosylated liposomes onNaAsO2 induced antioxidant enzymes, 
protection in hepatocytes and stellate cells 
  A single injection of NaAsO2 (100.06µM/kg b wt) resulted significant depletion of 
antioxidant level both in hepatocytes and stellate cells (Table-1). No significant 
protection was observed in the case of rats treated with free QC prior to arsenic treatment. 
Liposomal QC treatment prevented thiol depletion in stellate cells completely. But QC in 
galactosylated liposomes treatment prevented the depletion completely both in 
hepatocytes and stellate cells. 
 
Effect of QC in galactosylated liposome treatment on NaAsO2 induced hepatic 4-
hydroxy proline (4-HP) and collagen contents in rat liver 
   A single injection of NaAsO2 (100.06µM/kg b wt) induced an appreciable increase in 
hepatic collagen protein and 4-HP (Table-2). These increments of collagen and 4-HP 
were not reduced more by the treatment of free QC whereas these levels were decreased 
appreciably by the treatment of liposomal QC. QC in galactosylated liposome injection 
inhibited completely the collagen protein deposition and 4-HP increase in rat liver.  
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Effect of QC entrapped galactosylated liposomes on NaAsO2 mediated 
hepatocellular toxicity 
  Rats treated with a single dose of NaAsO2 developed significant hepatic damage as 
observed from elevated hepatospecific enzymes in serum.  The activity of AST and AP in 
serum was increased in NaAsO2 intoxicated animals.  The serum urea and creatinine 
levels were also increased upon NaAsO2 administration.  A single injection (i v) of 
liposome entrapped QC exerted a significant protection compared with free QC against 
NaAsO2 induced liver toxicity.  The degree of protection was observed maximally when 
galactose coated liposomal QC was injected (Table-3). 
 
Effect of galactosylated liposomal QC on NaAsO2 induced mitochondrial membrane 
microviscosity of hepatocytes and stellate cells 
   Arsenite induced a decrease of mitochondrial membrane microviscosity both in 
hepatocytes and stellate cells of rat liver. Liposomal QC treatment prevented the 
alteration in mitochondrial membrane microviscosity of stellate cells whereas QC in 
galactosylated liposome treatment protected mitochondrial membrane of both 
hepatocytes and stellate cells completely from any decrease mediated by NaAsO2 
treatment (Table-4). 
 
Quantitation of Quercetin in liver homogenate 
  In Table-5 QC levels were expressed per mg protein. By determining the amount of 
protein present in total liver homogenate the amount of uptake of QC and QC entrapped 
in different types of liposomes by liver was calculated. For liposomal QC, the uptake of 
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QC in the liver was found to be 50.29% of the injected dose where as only 25.61% of 
the injected dose was detected in the liver when free QC was injected. For galactosylated 
liposomal QC the uptake in the liver was to be 85.16%. 
 
Pathomorphology and histochemistry of the liver 
   Haematoxylin-Eosin-stained liver sections of normal rats showed (Fig.4a) the cords of 
normal hepatocytes, normal looking sinusoids lined by Kupffer cells. Central veins were 
normal. The histology was within normal limit. But the positive histological changes in 
the areas of hepatocellular and fatty metamorphosis, few focal areas of necrosis, Kupffer 
cell hyperplasia and localized fibrosis in the periportal region resulted from a single 
injection of NaAsO2 (Fig.4b). The induction for mild hyperplasia of Kupffer cell and the 
histology within normal limit appeared in the case of NaAsO2 intoxicated animals 
injected with galactosylated liposomal QC (Fig.4c). 
  Liver section of normal rats stained with Van Gieson exhibited very small amount of 
collagen in the periportal region (Fig.4d). But periportal region showed mild to moderate 
amount of collagen tissues when injected with a single injection of NaAsO2 (Fig.4e). The 
maximum protection from the deposition of collagen contents was observed when rats 
were treated with galactosylated liposomal QC prior to NaAsO2 injection (Fig.4f). 
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Discussion 
Exposure to the metalloid arsenic has become an increasingly recognized source of 
illness worldwide. Arsenic has a direct toxic effect on cellular respiration in liver 
mitochondria with an evidence of oxidative stress and hepatic collagenesis in human (Pi 
J, Yamauchi et al., 2002; Das et al., 2005). Hepatic fibrosis is a disease state 
characterized by exuberant synthesis and deposition of collagen in the extracellular 
matrix. Fibrogenesis is expressed by an increase in the hepatic hydroxyproline levels 
(Testa et al., 1993). The present observation also indicates that fibrogenesis could be 
induced with an increment of 4-HP by a single injection (s c) of NaAsO2 (100.06µM/kg b 
wt) (Table –2). 
  The exact mechanism of fibrogenesis by arsenic is not known. Arsenic induces the 
production of lactic acid because of an imbalance in cellular energy metabolism and the 
enol acid thus utilized by cells significantly increases the intracellular proline pool and 
collagen synthesis by stimulating the activity of prolyl hydroxylase.  
    A greater number of drugs including arsenic specific antidotes have been tested to 
reduce hepatic damage or necrosis and to inhibit liver fibrogenesis. However, none of 
them is liver specific or cell type specific (Guha Mazumder et al., 2001). Quercetin, a 
polyphenolic flavonoidal compound has been suggested in preventing the development of 
hepatic fibrosis (Lee et al., 2003). It is also known to reduce toxicant induced liver 
damage (Peres et al., 2000). Protective role of QC in galactosylated liposomes against 
carbontetrachloride induced hepatocellular damage have been shown at our previous 
observation (Mandal and Das, 2005). Hepatospecific liposomal QC (galactosylated 
liposome) with a high incorporation rate in hepatocytes has been formulated by us and 
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tested in reducing NaAsO2 induced liver fibrogenesis and hepatocellular damage. The 
increased hepatoprotective effect of galactosylated liposomes encapsulated QC compared 
to its free form that has been shown in this report against NaAsO2 induced liver damage 
could be explained by the observation of another group (Datta et al., 2003). They 
demonstrated that liposome entrapped compound interact with target cells at a much 
faster rate than that of free components. Moreover, by utilizing the galactosyl receptor of 
hepatocytes, galactosylated liposomes could be targeted to those non- phagocytic cells 
(Kawakami et al., 2001) with a simultaneous delivery to other types of hepatic cells of 
natural phagocytic activity. 
    Arsenic toxicity was reported as an inhibitory effect on cellular respiration at the level 
of mitochondria (Stanton et al., 2006). In our observations, the increased arsenic 
deposition in hepatocytes and stellate cells mitochondria from NaAsO2 treated rats are 
generating more ROS than normal animals (Fig.2; Table-1). When arsenic deposition in 
mitochondria is prevented by galactosylated liposomal QC treatment, NaAsO2 induced 
fibrogenesis is markedly reduced. Maintenance of mitochondrial membrane 
microviscosity i.e. reciprocal of membrane fluidity of hepatocytes and stellate cells could 
be achieved by the protective action of QC in galactosylated liposomes in cases where 
significant fall of mitochondrial membrane microviscosity takes place by the induction of 
NaAsO2 (Table-4).  
    Previous investigators have shown a deviation of the pro-oxidant/antioxidant balance 
in NaAsO2 treated rats with development of oxidative damage and a reduction in 
antioxidant status (Das et al., 2005). We also observed that liver injury was accompanied 
by the accumulation of arsenic with impaired activity and depletion of antioxidant status 
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in NaAsO2 induced rats. Reduction of liver injury was noticed by the improvement of 
antioxidant status with an increased concentration of QC and a marked reduction of 
arsenic content in liver by QC in galactosylated liposomes.  
    Our results indicate that galactosylated liposomal QC prevents arsenic deposition and 
protects liver from NaAsO2 induced collagen deposition and fibrogenesis (Fig.2, Table-
2). Administration of QC in galactosylated liposomes to rats protects those animals from 
arsenic induced liver fibrosis while free QC does not. It is expected that QC in 
galactosylated liposomes may be more protective than free QC or liposomal QC because 
of the enhanced intracellular accumulation of QC by selective tissue targeted delivery of 
galactosylated liposomes (Table-5). We demonstrated a positive correlation between 
arsenic accumulation and lipid peroxidation level in liver (Fig.3) as earlier report (Ramos 
et al., 1995). A single injection (s c) of NaAsO2 (100.06µM/kg) to rats resulted 
impairment in antioxidant status with a marked increase in arsenic content in liver. Our 
observation suggests that the mechanism of the protective effect of galactosylated 
liposomal QC against arsenic induced liver injury could be related primarily to the 
reduction of arsenic accumulation in liver. 
    As the levels of AST and AP increase in NaAsO2 induced hepatocellular injury, it 
appears that targeting of QC prevents hepatic cells against NaAsO2 induced membrane 
damage by decreasing the leakage of AST and AP in the circulation  (Table-3). The 
protective role of QC in galactosylated liposomes against NaAsO2 induced hepatotoxicity 
has also been confirmed by our histopathological and histochemical analysis (Fig.4). This 
approach of delivering a non-toxic herb origin polyphenolic compound QC selectively to 
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the liver might be useful in therapeutic application to prevent NaAsO2 induced liver 
fibrogenesis. 
   Further studies are planned to perform sub-chronic and chronic studies, in order to 
substantiate our claims that QC might be useful in therapeutic application in combating 
NaAsO2 induced fibrogenesis resultant from chronic arsenic exposure.  
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Legends for Figures 
Fig.1    Acute arsenic-induced lethality in the Albino Swiss rats. Rats (6 per group      per 
dose) were given NaAsO2 s c at the doses of 84.67 - 130.8µM/kg and the mortality was 
determined 24 h later. 
Fig.2  Arsenic concentrarion in mitochondria of hepatocytes (a) and stellate cells (b) of 
hepatic tissue. Values are mean ± SD for 5 rats. #P<0.001 significantly different from 
NaAsO2 treated. A. Normal, B. NaAsO2-treated, C. B + empty galactosylated liposome 
treated, D. B + free drug treated, E. B + liposomal QC treated, F. B + galactosylated 
liposomal QC treated. 
Fig.3  Correlation of mitochondrial arsenic content of hepatocytes (a) and stellate cells 
(b) with lipid peroxidation. For a, Y =0.1352X + 12.357, r = 0.97, P<0.001 whereas for b, 
Y=0.2191X +20.733, r =0.93, P<0.001. For a and b, □  NaAsO2 treated (A), ■  (A) + 
empty galactosylated liposome treated,  ♦ (A) + free drug treated, ◊ (A) + liposomal QC 
treated, ▲ (A) + galactosylated liposomal QC treated. 
            Fig.4 Histopathological examination of eosin-hematoxylin stained liver                       
section of normal and experimental rats with magnification x 400. (a) Physiological 
saline-treated control, (b) NaAsO2-treated, (c) NaAsO2 + galactosylated liposomal QC 
(8.9µM/kg b wt) treated.  
Histochemical examination of Van Gieson stained liver section of normal and 
experimental rats with magnification x 400. (d) Physiological saline-treated control, (e) 
NaAsO2-treated, (f) NaAsO2 + galactosylated liposomal QC (8.9µM/kg b wt) treated. 
↓indicates fibrosis, ↓↓indicates fattymetamorphosis, ↓↓↓indicates necrosis. 
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Table-1. Effect of QC in free, liposome encapsulated and galactosylated liposome 
encapsulated forms on the changes in various components of antioxidant defence system 
in hepatocytes (HP) and Stellate (ST) cells  of rat liver by the induction of NaAsO2. 
 
GPx µ-mol 
NADPH 
oxidation/m
in/mg 
protein 
G6PDH n-
mol NADP 
reduced/min/
mg protein 
GR µ-mol of 
NADPH 
oxidation/min/
mg protein 
Catalase µmol 
H2O2 
reduced/min/
mg protein 
GST n-mol  
produced/min/
mg protein 
 
   HP    ST    HP    ST    HP    ST    HP    ST   HP   ST 
Normal 7.69 
± 
0.31 
9.25 
± 
0.57 
8.25 
± 
0.41 
12.31 
± 0.61 
23.17 
± 1.56 
34.32 
± 1.38 
6.81 
± 
0.13 
9.22 ± 
0.21 
117.82 
± 
19.23 
134.92  
± 
21.71 
NaAsO2 
treated (A) 
3.78 
± 
0.17
∗ 
4.55 
± 
0.29 
∗ 
4.02 
± 
0.22 
∗ 
6.05 ± 
0.30 ∗ 
11.29 
± 0.92 
∗ 
16.71 
± 0.87 
∗ 
3.31 
± 
0.08 
∗ 
4.49 ± 
0.13 ∗ 
56.79 
± 9.09 
∗ 
68.25  
± 
10.08 
∗ 
(A) + 
Empty 
galactosylat
ed liposome 
treated 
3.92 
± 
0.12 
4.76 
± 
0.23 
4.16 
± 
0.24 
6.35 ± 
0.33 
11.48 
± 0.36 
16.92 
± 0.54 
3.40 
± 
0.02 
4.61 ± 
0.15 
57.85 
± 7.31 
69.62 
± 6.56 
(A) + Free 
QC treated 
4.47 
± 
0.23 
5.37 
± 
0.26 
4.78 
± 
0.23 
7.14 ± 
0.38 
13.38 
± 1.71 
19.73 
± 1.05 
3.57 
± 
0.09 
5.29 ± 
0.18 
61.42 
± 
11.28 
76.88  
± 
13.17 
(A) + QC-
entrapped 
liposome 
treated 
5.12 
± 
0.26 
∗ 
8.82 
± 
0.48 
∗ 
5.95 
± 
0.41 
∗ 
11.96 
± 0.59 
∗ 
18.32 
±1.07 
∗ 
33.34 
± 1.72 
∗ 
4.06 
± 
0.12 
∗ 
8.69 ± 
0.27 ∗ 
70.27 
± 
13.76 
# 
126.29  
± 
17.81 
∗ 
(A) + QC-
entrapped in 
galactosylat
ed liposome 
treated 
7.27 
± 
0.44 
∗ 
9.07 
± 
0.45 
∗ 
8.05 
± 
0.40 
∗ 
11.86 
± 0.59 
∗ 
22.46 
± 1.21 
∗ 
32.07 
± 1.65 
∗ 
5.96 
± 
0.31 
∗ 
8.72 ± 
0.29 ∗ 
102.39 
± 
17.83 
∗ 
129.73  
± 
19.93 
∗ 
 
Results are expressed as mean ± SD. NaAsO2 treated group was compared with normal 
and the value was significantly different where ∗ = P<0.001. Experimental groups QC 
entrapped in liposome and QC in galactosylated liposomal group were also compared 
with NaAsO2 treated group and in all those cases ∗ = P<0.001 and # = P<0.01.  
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Table-2. Effect of QC and liposomal QC treatment on collagen and 4-hydroxy proline (4-
HP) levels in liver following NaAsO2 treatment. 
 
Groups Hepatic collagen (µg/mg 
protein) 
Hepatic 4-HP (µg protein) 
Normal 10.93 ± 1.86 22.18 ± 3.14 
NaAsO2 treated (A) 19.27 ± 2.13 ∗ 83.21 ± 7.19 ∗ 
(A) + Empty 
galactosylated liposome 
treated 
19.02 ± 1.14 81.78 ± 5.45 
(A) + Free QC treated 18.52 ± 1.96 76.52 ± 5.77 
(A) + Liposomal QC 
treated 
15.19 ± 1.67 ∗ 61.73 ± 4.88 ∗ 
(A) + QC in galactosylated 
liposome treated 
11.21 ± 1.73 ∗ 26.36 ± 4.11 ∗ 
 
Results are expressed as mean ± SD. NaAsO2 treated group was compared with normal 
and the values were significantly different where ∗ = P<0.001 for hepatic collagen and 4-
HP. Experimental groups QC entrapped in liposome and QC in galactosylated liposomal 
group were also compared with NaAsO2 treated group and in all those cases ∗ = P<0.001 
for hepatic collagen and 4-HP. 
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Table-3. Effect of liposomal-encapsulated QC injection (i.v) on blood serum 
biochemical parameters in NaAsO2-induced hepatocellular injury. 
 
 
Results are expressed as mean ± SD of five animals. NaAsO2 treated group was 
compared with normal and the value was significantly different where ∗ = P<0.001. 
Experimental groups (galactosylated liposomal QC and liposomal QC group) were also 
compared with NaAsO2 treated group and in all those cases ∗ =P<0.001. 
 
 
 
 
 
Experimental groups Parameter Normal NaAsO2-
treated 
group (A) (A)+empty galactosylated 
liposome 
treated 
(A)+free 
QC treated 
(8.9µM/Kg 
b wt) 
(A)+liposomal 
QC treated 
(8.9µM/Kg b 
wt) 
(A)+ 
galactosylated 
liposomal  
QC treated 
(8.9µM/Kg b 
wt) 
Alkaline 
phosphatase 
(U/l) 
280±11.70 818±36.60 
∗ 
808±16.50 824±33.81 513.55±11 ∗ 307.78±14.43 
∗ 
SGPT 
(IU/l) 
36.86±2.18 89.71±6.42 
∗ 
85.52±4.51 94.11±4.61 67.43±3.97 ∗ 49.14±2.21 ∗ 
Urea (g/l) 0.45±0.04 1.48±0.08 
∗ 
1.40±0.02 1.61±0.08 0.71±0.09 ∗ 0.46±0.03 ∗ 
Creatinine 
(mg/l) 
13.4±1.84 74.17±5.49 
∗ 
72.43±2.67 76.8±4.86 44.7±3.18 ∗ 14.7±3.18 ∗ 
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Table-4. Effect of QC in galactosylated liposome treatment on the NaAsO2 induced 
mitochondrial membrane microviscosity, ([r0/r-1] –1) of rat hepatocytes (HP) and stellate 
(ST) cells. 
                   Membrane microviscosity [r0/r-1] –1 
                HP                 ST  
Normal 0.677±0.073 0.687±0.024 
NaAsO2 treated (A) 0.216±0.021* 0.274±0.019* 
(A)+empty 
galactosylated 
liposome treated 
0.231±0.018* 0.286±0.027* 
(A)+free QC treated 0.340±0.089* 0.382±0.046* 
(A)+ liposomal QC 
treated 
0.312±0.099 0.606±0.052# 
(A)+ QC in 
galactosylated 
liposome treated 
0.661±0.045# 0.666±0.061# 
 
Values are mean ± SD for 5 rats. *P<0.001 significantly different from normal.  
#P<0.001 significantly different from NaAsO2 treated. 
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Table-5. Quercetin level in liver homogenate from rats treated with QC (in tween 80), 
liposomal QC and galactosylated liposomal QC. 
Galactosylated liposomal QC  
Free QC Liposomal QC QC1 QC2 QC3 QC4 
QC 
concentration in 
liver 
homogenate 
(nM/mg protein) 
0.83 ± 0.17a 1.63 ± 0.32a,b 
0.36 ± 
0.09a,b 
0.92 ± 
0.18a,b 
2.76 ± 
0.54a,b 
1.92 ± 
0.19a,b 
% of injected 
QC in whole 
liver 
25.61 50.29 52.17 57.18 85.16 48.65 
 
Rats received   8.9µM/kg b.wt intravenous injection of both of the free QC and liposomal 
QC, and galactosylated liposomal QC (QC1→ 2.22µM/Kg b wt, QC2→ 4.45µM/Kg b 
wt, QC3→ 8.90µM/Kg b wt, QC4→ 13.35µM/Kg b wt). a values expressed as mean ± 
SD (n = 5). b values are significantly different ( p <0.001) from free QC a. 
 
 
 
 
 




